Yield10 Bioscience

About Yield10 Bioscience

Yield10 Bioscience, Inc. operates as an agricultural bioscience company with a strategic focus on developing Camelina sativa as a platform crop for producing valuable seed products. Founded in 2005 and headquartered in Woburn, Massachusetts, the company aims to address the increasing demand for sustainable materials and nutritional products. The leadership team, including President and CEO Oliver Peoples, Chief Scientific Officer Kristi Snell, and Vice President of Research and Development Tim Swore, possesses deep expertise in plant engineering and metabolic pathways. Dr. Peoples, a co-founder, has a notable background in molecular biology and has been instrumental in guiding the company's focus on PHA bioplastics and other high-value Camelina-derived products.

The core of Yield10's business revolves around its proprietary genetic advancements in Camelina, an oilseed crop known for its resilience and suitability for cultivation on marginal lands. The company's business model is centered on establishing a grain contracting business, supplying its elite Camelina varieties to growers. This positions Yield10 to capitalize on the significant market demand for low-carbon intensity feedstock oils. These oils are critical for the production of renewable diesel and sustainable aviation fuel (SAF), markets that are expanding due to regulatory shifts and corporate sustainability commitments.

Beyond biofuels, Yield10 is engineering Camelina to produce omega-3 fatty acids, specifically EPA and DHA. These oils are targeted for high-value applications in the pharmaceutical, nutraceutical, and aquafeed markets, offering a plant-based alternative to traditional marine sources. Another forward-looking application is the production of polyhydroxyalkanoates (PHAs), which are biodegradable bioplastics, directly within the Camelina seed. This technology aims to provide a cost-effective and sustainable material for various consumer and industrial products. By developing Camelina as a versatile factory crop, Yield10 is building a multi-faceted revenue stream based on licensing its advanced genetics and selling harvested grain for distinct, high-demand end markets. The company's public listing on the Nasdaq under the symbol YTEN provides it with access to capital markets to fund its research, development, and commercialization efforts.